Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPOXA: IP Oxaliplatin + FOLFIRI + Bevacizumab in Peritoneal Carcinosis
NCT02866903Phase 2Unknown
- Sponsor
- Hospices Civils de Lyon
- Start
- May 2017
- Primary completion
- Mar 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in peritoneal carcinomatosis (PC) and colorectal cancer (CRC), sponsored by Hospices Civils de Lyon. Primary endpoints: Adverse events (NCI CTCAE v4.0) at 14 days and Dose Limiting Toxicities at 14 days. Status: unknown.
02
Drugs
oxaliplatin
03
Conditions
peritoneal carcinomatosis (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02866903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02866903.